MASSIVE Project Candidates
Sarcopenia (Next-generation)
DiscoveryAI-driven discovery of novel MasR activators in collaboration with LynxKite.
Key Facts
Indication
Sarcopenia (Next-generation)
Phase
Discovery
Status
AI-driven discovery of novel MasR activators in collaboration with LynxKite.
Company
About Biophytis
Biophytis is a clinical-stage biotech focused on geroscience, aiming to treat age-related diseases by targeting the hallmarks of aging. Its core strategy revolves around three pillars: a proprietary AI-accelerated longevity research platform, the advanced Phase 3-ready program BIO101 for sarcopenia, and a parallel program for BIO101 in obesity as a combination therapy with GLP-1 agonists. The company has secured strategic partnerships and funding to advance its pipeline, including a landmark joint venture in Asia and an expanded AI collaboration with LynxKite.
View full company profile